Patents by Inventor Gholamreza Hassanzadeh Ghassabeh

Gholamreza Hassanzadeh Ghassabeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CALRETICULIN NANOBODIES
    Publication number: 20230416348
    Abstract: Provided are nanobodies that bind human calreticulin, fusion proteins including the nanobodies, pharmaceutical compositions including the nanobodies or fusion proteins, and radioconjugates of the nanobodies or fusion proteins.
    Type: Application
    Filed: May 24, 2023
    Publication date: December 28, 2023
    Inventors: GHOLAMREZA HASSANZADEH GHASSABEH, STEVE SCHOONOOGHE, HELEN KOTANIDES
  • ANTI-DLL3 ANTIBODIES AND METHODS OF USE
    Publication number: 20230227577
    Abstract: The present disclosure provides anti-DLL3 binding constructs, such as anti-DLL3 single domain antibodies, as well as polynucleotide encoding the same. Further provided are multispecific binding constructs comprising the DLL3 binding domains described herein and polynucleotides encoding the same. Methods of production of the anti-DLL3 binding constructs and their use in the treatment of cancer are also provided herein.
    Type: Application
    Filed: May 5, 2021
    Publication date: July 20, 2023
    Inventors: Gholamreza HASSANZADEH GHASSABEH, Lorena LERNER, Sonia FEAU, Christophe QUÉVA
  • Serum albumin binding agents
    Patent number: 11155607
    Abstract: The present invention relates to polypeptides comprising an immunoglobulin variable domain, binding with high affinity to serum albumin for increasing the half-life of therapeutic agents and compositions, in particular for therapeutic agents comprising multispecific immunoglobulin variable domains. Also provided herein are methods for the production of polypeptides comprising serum albumin binding immunoglobulin variable domains of the present invention.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 26, 2021
    Assignee: VIB VZW
    Inventors: Gholamreza Hassanzadeh Ghassabeh, Steve Schoonooghe, Erik Depla
  • SERUM ALBUMIN BINDING AGENTS
    Publication number: 20200255504
    Abstract: The present invention relates to polypeptides comprising an immunoglobulin variable domain, binding with high affinity to serum albumin for increasing the half-life of therapeutic agents and compositions, in particular for therapeutic agents comprising multispecific immunoglobulin variable domains. Also provided herein are methods for the production of polypeptides comprising serum albumin binding immunoglobulin variable domains of the present invention.
    Type: Application
    Filed: July 17, 2018
    Publication date: August 13, 2020
    Inventors: Gholamreza Hassanzadeh Ghassabeh, Steve Schoonooghe, Erik Depla
  • Markers for alternatively activated macrophages
    Patent number: 7514217
    Abstract: The present invention relates to novel markers for alternatively activated macrophages. More specifically, the present invention relates to the use of galactose-type C-type lectins as surface markers that allows rapid identification and sorting of the alternative macrophages. Such identifications can be useful in diseases where there is an imbalance between proinflammatory and anti-inflammatory immune reactions.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: April 7, 2009
    Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Vrije Universiteit Brussel
    Inventors: Geert Raes, Gholamreza Hassanzadeh Ghassabeh, Patrick De Baetselier
  • Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells
    Publication number: 20080199472
    Abstract: The present invention reates to the use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells. More specifically, the present invention relates to a domain of a Secretory Leukocyte Protease Inhibitor (SLPI) to modulate tumor invasiveness and/or metastasis. It further relates to compounds, such as antibodies, that interact with the domain and repress the tumor invasiveness and/or the metastasis.
    Type: Application
    Filed: February 14, 2008
    Publication date: August 21, 2008
    Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Vrije Universiteit Brussel
    Inventors: Hilde Revets, Patrick De Baetselier, Nick Devoogdt, Gholamreza Hassanzadeh Ghassabeh
  • Novel markers for alternatively activated macrophages
    Publication number: 20060183162
    Abstract: The present invention relates to novel markers for alternatively activated macrophages. More specifically, the present invention relates to the use of galactose-type C-type lectins as surface markers that allows rapid identification and sorting of the alternative macrophages. Such identifications can be useful in diseases where there is an imbalance between proinflammatory and anti-inflammatory immune reactions.
    Type: Application
    Filed: March 9, 2006
    Publication date: August 17, 2006
    Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Vrije Universiteit Brussel
    Inventors: Geert Raes, Gholamreza Hassanzadeh Ghassabeh, Patrick Baetselier
  • Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells
    Publication number: 20060111294
    Abstract: The present invention relates to the use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells. More specifically, the present invention relates to a domain of a Secretory Leukocyte Protease Inhibitor (SLPI) to modulate tumor invasiveness and/or metastasis. It further relates to compounds, such as antibodies, that interact with said domain and repress the tumor invasiveness and/or the metastasis.
    Type: Application
    Filed: November 7, 2005
    Publication date: May 25, 2006
    Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Vrije Universiteit Brussel
    Inventors: Hilde Revets, Patrick De Baetselier, Nick Devoogdt, Gholamreza Hassanzadeh Ghassabeh